Featured News

Researchers study why people, even in the same family, have different coronavirus symptoms, from serious to mild. “We really need to figure this out.”

In this Stanford Department of Medicine Grand Rounds presentation, experts discuss the status of COVID-19 vaccine development. Presenter: Kari Nadeau, MD - Naddisy Foundation Professor of Pediatric Food Allergy, Immunology and Asthma; Professor of Pediatrics; Senior Fellow at the Woods Institute for the Environment and Professor by courtesy of Otolaryngology Head and Neck Surgery At LPCH

Throughout her career, Professor Nadeau has been a pioneer in the field of Translational Allergy and Immunology, both defining the mechanisms of new therapies and then translating them clinically to make transformative changes in patient care. She has led research in oncology, transplant and autoimmune trials and is a member of the National Steering Committee for the intramural clinical research programs at the NIH. During the current COVID-19 pandemic, she led one of the key successful NIH NIAID-funded Remdesivir clinical trials as a potential therapeutic for SARS-CoV-2. On April 29th, Dr. Anthony Fauci, the Director of NIH and a current member of the US Coronavirus Task Force, announced that Remdesivir will become the “new standard of care” for COVID-19.

Stanford Health Care gave us exclusive access to show how coronavirus antibody testing works. So we followed two caregivers and their blood, through the testing process.

Studies from serum samples could transform our understanding of the spread of COVID-19, but what antibodies alone say about immunity is not yet clear.